

## Capecitabine 825mg/m<sup>2</sup> and RT-7 day

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement status
Locally advanced rectal cancer	C20	00586a	CDS

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Capecitabine is administered twice daily on day 1-5 concurrently with radiotherapy for a maximum of 5-6 cycles (one cycle is equal to 7 days).

Day	Drug	Dose	Route	Cycle
1-5	Capecitabine <sup>a</sup>	825mg/m <sup>2</sup> twice daily <sup>b</sup>	PO with food <sup>c</sup>	Every 7 days for a maximum of 5-6 cycles with radiotherapy
<sup>a</sup> See dose modifications section for patients with identified partial DPD deficiency <sup>b</sup> (total daily dose = 1650mg/m <sup>2</sup> ) <sup>c</sup> Capecitabine is available in 150mg and 500mg tablets. The dose to be administered must take this into consideration. Please refer to the <a href="#">NCCP Dose Banding Tables</a> Capecitabine should be taken with plenty of water within 30 minutes of eating				

### ELIGIBILITY:

- Indications as above
- ECOG status 0-1

### EXCLUSIONS:

- Hypersensitivity to capecitabine or any of the excipients
- Known complete DPD deficiency
- History of severe and unexpected reactions to fluoropyrimidine therapy
- Pregnancy and lactation
- Severe hepatic or renal impairment

### PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 1 of 7
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a> This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a>		

## TESTS:

### Baseline tests:

- FBC, renal and liver profile
- DPD testing prior to first treatment with capecitabine using phenotype and/or genotype testing unless patient has been previously tested

### Regular tests:

- FBC, renal and liver profile prior to each cycle.

### Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Consider a reduced starting dose in patients with identified partial DPD deficiency.
  - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
- Any dose modification should be discussed with a Consultant.

## Haematological:

**Table 1: Dose modification of capecitabine based on haematological toxicity**

ANC (x 10 <sup>9</sup> /L)		Platelets (x 10 <sup>9</sup> /L)	1st Event Dose	2 <sup>nd</sup> Event Dose	3 <sup>rd</sup> Event Dose	4 <sup>th</sup> Event Dose
≥ 1.5	and	≥ 75	100%	100%	100%	100%
1-1.49	or	50 – 74.9	Delay* then 100%	Delay* then 75%	Delay* then 50%	Discontinue
0.5-0.99	or	25- 49.9	Delay* then 75%	Delay* then 50%	Discontinue	Discontinue
< 0.5	or	< 25	Discontinue or delay* then 50%	Discontinue	Discontinue	Discontinue

\*Delay until ANC ≥ 1.5x 10<sup>9</sup>/L and platelets ≥ 75x10<sup>9</sup>/L

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 2 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Renal and Hepatic Impairment:

**Table 2: Dose modification of capecitabine in renal and hepatic impairment**

Renal Impairment		Hepatic Impairment
Cr Cl (ml/min)	Dose	In the absence of safety and efficacy data in patients with hepatic impairment, capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis.
≥ 30	100% dose	
<30	Discontinue treatment	
Reference Table 6 for dose modification of capecitabine in treatment related hepatotoxicity		

## Management of adverse events:

Table 3 shows the recommended dose modifications of capecitabine for those toxicities which are not individually specified:

**Table 3: Capecitabine dose reduction schedule based on toxicity (Any)**

Toxicity grades*	Dose changes within a treatment cycle	Dose adjustment for next cycle/dose (% of starting dose)
<b>Grade 1</b>	Maintain dose level	Maintain dose level
<b>Grade 2</b>		
• 1 <sup>st</sup> appearance	Interrupt until resolved to grade 0-1	100%
• 2 <sup>nd</sup> appearance		75%
• 3 <sup>rd</sup> appearance		50%
• 4 <sup>th</sup> appearance	Discontinue permanently	
<b>Grade 3</b>		
• 1 <sup>st</sup> appearance	Interrupt until resolved to grade 0-1	75%
• 2 <sup>nd</sup> appearance		50%
• 3 <sup>rd</sup> appearance	Discontinue permanently	
<b>Grade 4</b>		
• 1 <sup>st</sup> appearance	Discontinue permanently or If consultant deems it to be in patient's best interest to continue, interrupt until resolved to grade 0-1	50%
• 2 <sup>nd</sup> appearance	Discontinue permanently	
Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy		

\*Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 3 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

**Table 4: Dose Modification of capecitabine for diarrhoea**

Grade	Diarrhoea	Dose changes within a treatment cycle	Dose adjustment for next cycle/dose (% of starting dose)
0-1	Increase of 2 to 3 stools/day or nocturnal stools	Maintain dose level	Maintain dose level
2	Increase of 4 to 6 stools/day or nocturnal stools		
	<ul style="list-style-type: none"> <li>1<sup>st</sup> appearance</li> </ul>	Interrupt until resolved to grade 0-1	100%
	<ul style="list-style-type: none"> <li>2<sup>nd</sup> appearance</li> </ul>		75%
	<ul style="list-style-type: none"> <li>3<sup>rd</sup> appearance</li> </ul>		50%
	<ul style="list-style-type: none"> <li>4<sup>th</sup> appearance</li> </ul>	Discontinue permanently	
3	Increase of 7 to 9 stools/day or incontinence		
	<ul style="list-style-type: none"> <li>1<sup>st</sup> appearance</li> </ul>	Interrupt until resolved to grade 0-1	75%
	<ul style="list-style-type: none"> <li>2<sup>nd</sup> appearance</li> </ul>		50%
	<ul style="list-style-type: none"> <li>3<sup>rd</sup> appearance</li> </ul>	Discontinue permanently	
4	Increase of 10 or more stools/day or grossly bloody diarrhoea; may require parenteral support		
	<ul style="list-style-type: none"> <li>1<sup>st</sup> appearance</li> </ul>	Discontinue permanently or If consultant deems it to be in patient's best interest to continue, interrupt until resolved to grade 0-1	50%
	<ul style="list-style-type: none"> <li>2<sup>nd</sup> appearance</li> </ul>	Discontinue permanently	

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy

## Hand foot syndrome:

**Table 5: Dose modification of capecitabine in hand foot syndrome**

Toxicity Grade		Dose Modification
Grade 1	Skin changes (e.g., numbness, dysesthesia, paraesthesia, tingling, erythema) with discomfort not disrupting normal activities	100% Dose
Grade 2	Skin changes (e.g., erythema, swelling) with pain affecting activities of daily living	Withhold treatment until event resolves or decreases in intensity to grade 1.
Grade 3	Severe skin changes (e.g., moist desquamation, ulceration, blistering) with pain, causing severe discomfort and inability to work or perform activities of daily living	Withhold treatment until event resolves or decreases in intensity to grade 1. Subsequent doses of capecitabine should be decreased

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 4 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a>  <i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Treatment related hepatotoxicity

**Table 6: Dose modification of capecitabine in treatment related hepatotoxicity**

Bilirubin		ALT, AST	Dose Modification
> 3.0 x ULN	or	> 2.5 x ULN	Withhold treatment until bilirubin decreases to $\leq 3.0$ x ULN or ALT, AST decrease to $\leq 2.5$ x ULN

## SUPPORTIVE CARE:

**EMETOGENIC POTENTIAL:** Minimal to low (**Refer to local policy**).

**PREMEDICATIONS:** Not usually required

## OTHER SUPPORTIVE CARE:

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

*The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.*

- **Diarrhoea and dehydration:** This may be dose limiting. Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.
- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Cardiotoxicity:** Angina-like chest pain, tachycardia, arrhythmias, heart failure, myocardial infarction and cardiac arrest may occur with capecitabine especially in patients with a prior history of coronary artery disease.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency:** DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil, capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.
- **Hand-foot syndrome (HFS)**, also known as palmar-plantar erythrodysesthesia (PPE), is a common side effect associated with capecitabine (see Table 5 for dose modification of capecitabine for HFS).

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 5 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## DRUG INTERACTIONS:

- Capecitabine enhances the anticoagulant effect of warfarin. Patients taking coumarin derivative anticoagulants should be monitored regularly for alterations in their coagulation parameters and the anti-coagulant dose adjusted accordingly.
- Sorivudine inhibits dihydropyrimidine dehydrogenase thus increasing its toxicity. Therefore, capecitabine must not be administered concomitantly with sorivudine or its chemically related analogues.
- Patients taking phenytoin or fosphenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
- Current drug interaction databases should be consulted for more information.

## ATC CODE:

Capecitabine - L01BC06

## REFERENCES:

1. O'Connell MJ, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol*. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753.
2. Hofheinz RD, Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol*. 2012 Jun;13(6):579-88. doi: 10.1016/S1470-2045(12)70116-X.
3. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>
4. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>
5. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V1 2018. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp%20antiemetic%20classification%20document%20v1%202018.pdf>
6. [HPRA](#) Direct Healthcare Professional Communication. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Accessed Aug 2020 Available at: [https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-\(i-v\)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0](https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-(i-v)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0)
7. Capecitabine (Xeloda®) Summary of Product Characteristics. Last updated: 30/08/2019. Accessed Sept 2020. Available at [https://www.ema.europa.eu/en/documents/product-information/xeloda-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/xeloda-epar-product-information_en.pdf)

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 6 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

Version	Date	Amendment	Approved By
1	06/12/2019		Prof Maccon Keane
2	3/9/2020	Reviewed. Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia	Prof Maccon Keane

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

NCCP Regimen: Capecitabine 825mg/m <sup>2</sup> and RT -7 Day	Published: 06/12/2019 Review: 23/09/2025	Version number: 2
Tumour Group: Gastrointestinal NCCP Regimen Code: 00586	ISMO Contributor: Prof Maccon Keane	Page 7 of 7
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		